CN112624950A - Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine - Google Patents
Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine Download PDFInfo
- Publication number
- CN112624950A CN112624950A CN202011437970.XA CN202011437970A CN112624950A CN 112624950 A CN112624950 A CN 112624950A CN 202011437970 A CN202011437970 A CN 202011437970A CN 112624950 A CN112624950 A CN 112624950A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- difluorophenyl
- pyrrolidine
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
The invention belongs to the technical field of chemical pharmacy, and relates to a synthetic method of (R) -2- (2, 5-difluorophenyl) pyrrolidine. The synthesis method comprises the following steps: (1) the compound of the formula 1 and a chiral inducing reagent (R) -tert-butyl sulfenamide are subjected to dehydration condensation reaction to obtain a compound of a formula 2; (2) carrying out addition reaction on the compound shown in the formula 2 and a Grignard reagent to obtain a compound shown in a formula 3; (3) the compound in the formula 3 is subjected to reduction/cyclization reaction with trifluoroacetic acid and triethylsilane to obtain a compound in a formula 4; (4) resolving the compound of formula 4 with (D) -malic acid to obtain (R) -2- (2, 5-difluorophenyl) pyrrolidine D malate compound with EE > 98% of formula 5; (5) and dissociating the compound of the formula 5 by using a sodium hydroxide solution to obtain the (R) -2- (2, 5-difluorophenyl) pyrrolidine. The synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine has the advantages of low cost, high optical purity, simplified subsequent separation process, easily obtained raw materials, mild process conditions and suitability for large-scale production.
Description
Technical Field
The invention belongs to the technical field of chemical pharmacy, and relates to a synthetic method of (R) -2- (2, 5-difluorophenyl) pyrrolidine.
Background
23 months 9 and 2019, Baier company announces that the drug larotrecitinib for precisely treating the tumors under the flag obtains the marketing permission of European Union. Larotrectinib, as the first oral TRK inhibitor, is specially used for treating tumors with NTRK gene fusion, and is the first approved anti-cancer drug in European Union without tumor type differentiation.
The biggest difference from the traditional targeting drugs is that Larotrectinib is not specific to tumors at a certain anatomical position, but is developed as a broad-spectrum tumor drug and is used for all adult or child solid tumor patients carrying NTRK fusion genes.
TRK gene fusion refers to fusion of NTRK gene family members (NTRK1, NTRK2, NTRK3) with another unrelated gene due to chromosomal variation to generate conformationally activated aberrant TRK fusion proteins. The TRK fusion protein acts as a tumor driving factor and drives the diffusion and growth of TRK fusion tumor. NTRK gene fusion can occur anywhere in the body, and therefore, TRK fusion tumors may occur in a variety of adult and pediatric solid tumors. According to market related individuals, NTRK mutations occur in less than 1% of most solid tumor types, but are common in some rare cancers such as adult salivary cancer and infant fibrosarcoma. In the united states, 2000 to 3000 people are estimated to have NTRK-associated cancer annually. TRK fusion occurs early in tumorigenesis and persists during tumor growth and dissemination.
Larotrectinib is a potent, oral, selective inhibitor of Tropomyosin Receptor Kinases (TRKs) intended to directly target TRK (including TRKA, TRKB, and TRKC), closing off signaling pathways leading to TRK fusion tumor growth. At present, Larotrectinib is proved to have a lasting anti-tumor activity effect and good tolerance in TRK fusion cancers of wide ages and tumor types, and the treatment efficiency of the Larotrectinib can reach 75% for 17 tumors such as lung cancer, thyroid cancer, melanoma, GIST, colon cancer, soft tissue sarcoma, salivary gland tumor, infant fibrosarcoma and the like.
The structural formula of Larotrectinib is as follows:
the (R) -2- (2, 5-difluorophenyl) pyrrolidine with the following structure is the most important intermediate in the synthesis process and the most expensive intermediate.
In the prior art, the synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine mainly comprises the following two methods:
the method comprises the following steps:
the synthesis method has the following problems: the process route is too long, the raw materials are expensive, the selectivity of chiral reduction is poor, the DE value is about 80 percent, diastereoisomers can be separated only by column chromatography, and the safety is not good when the metal compound sodium hydride is used in the cyclization reaction.
The method 2 comprises the following steps:
the synthesis method has the following problems: noble metals and coordination compounds are used in the chiral reduction process, so the chiral reduction process is expensive and difficult to recover; SEC-BuLi, a very active/hazardous organometallic compound, is used in the synthesis and therefore this step needs to be cryogenic (-78 ℃ C.) and therefore is less cost-effective and commercially viable.
Disclosure of Invention
The invention aims to provide a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, which has the advantages of low cost, high optical purity, simplified subsequent separation process, easily obtained raw materials, mild process conditions and suitability for large-scale production.
To achieve this object, in a basic embodiment, the present invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, comprising the steps of:
(1) the compound of the formula 1 and a chiral inducing reagent (R) -tert-butyl sulfenamide are subjected to dehydration condensation reaction to obtain a compound of a formula 2;
(2) carrying out addition reaction on the compound shown in the formula 2 and a Grignard reagent to obtain a compound shown in a formula 3;
(3) the compound in the formula 3 is subjected to reduction/cyclization reaction with trifluoroacetic acid and triethylsilane to obtain a compound in a formula 4;
(4) resolving the compound of formula 4 with (D) -malic acid to obtain (R) -2- (2, 5-difluorophenyl) pyrrolidine D malate compound with EE > 98% of formula 5;
(5) the compound of the formula 5 is dissociated by sodium hydroxide solution to obtain (R) -2- (2, 5-difluorophenyl) pyrrolidine
The relevant principle of the invention is as follows:
(1) synthesis of compounds of formula 2:
the compound of formula 1 and a chiral inducing reagent (R) -tert-butyl sulfinamide are subjected to dehydration condensation reaction to obtain a compound of formula 2.
1) Ethyl titanate is used as a dehydrating agent, tetrahydrofuran is used as a solvent, and the Schiff base type 2 compound is obtained through dehydration condensation.
Reaction conditions are as follows: dissolving 2, 5-difluorobenzaldehyde in 5 volumes of tetrahydrofuran, adding 2 equivalents of ethyl titanate, adding 1.5 equivalents of R-tert-butylsulfinamide, heating to 65 ℃, and reacting at normal pressure for 2 hours under the protection of nitrogen.
2) Isopropyl titanate is used as a dehydrating agent, tetrahydrofuran is used as a solvent, and the Schiff base 2 compound is obtained by dehydration condensation.
Reaction conditions are as follows: dissolving 2, 5-difluorobenzaldehyde in 5 volumes of tetrahydrofuran, adding 2 equivalents of isopropyl titanate, adding 1.5 equivalents of R-tert-butylsulfinamide, heating to 65 ℃, and reacting under normal pressure for 2 hours under the protection of nitrogen.
3) Anhydrous copper sulfate can be used as a dehydrating agent, methylene dichloride is used as a solvent, and the Schiff base 2 compound is obtained by dehydration condensation.
Reaction conditions are as follows: dissolving 2, 5-difluorobenzaldehyde and R-tert-butylsulfinamide in 1:1.2 equivalent in dichloromethane, adding 2.5 equivalent of anhydrous copper sulfate, heating to 30-40 ℃ for reaction, and completing the reaction for 3-4 hours.
(2) Synthesis of compounds of formula 3:
and (3) carrying out addition reaction on the compound of the formula 2 and a Grignard reagent to obtain a compound of a formula 3.
1) The Grignard reagent of 1M is prepared by reacting 2- (2-bromoethyl) -1, 3-dioxane and magnesium metal powder in tetrahydrofuran solution, or the Grignard reagent of 1M is prepared by reacting 2- (2-bromoethyl) -1, 3-dioxane and magnesium metal powder in tetrahydrofuran solution, and the solvent for addition reaction can be selected from tetrahydrofuran, diethyl ether, dichloromethane, preferably tetrahydrofuran.
2) The reaction ratio of the Schiff base and the format reagent is preferably 1:1.5 equivalent.
3) The addition reaction temperature is preferably-30 ℃, the reaction time is 3-5 hours, and the chiral selectivity is best.
(3) Synthesis of compounds of formula 4:
the compound of formula 3 has high chiral selectivity, DE value is more than 90%, and the compound of formula 4 is obtained by reduction/cyclization reaction with trifluoroacetic acid and triethylsilane.
1) The deliquifying inducing agent and acetal are preferably a system of trifluoroacetic acid and water, preferably in a volume ratio of 95: 5.
2) The reducing agent is preferably triethylsilane.
3) The reaction temperature is preferably 0-30 ℃ and the reaction time is 12-24 hours.
(4) Synthesis of compounds of formula 5:
the compound of formula 4 has very high chiral selectivity, EE is more than 90%, and the (R) -2- (2, 5-difluorophenyl) pyrrolidine D malate compound with EE more than 98% of formula 5 can be obtained by resolution with (D) -malic acid.
1) The chiral acid can be D-tartaric acid, D-malic acid, D-mandelic acid, preferably D-malic acid.
2) The alcohol solvent is preferably ethanol, and the volume of 5-10 is the best.
3) The reaction temperature is 25 to 70 ℃.
D-malic acid is adopted for resolution, ethanol is used as a solvent for resolution and crystallization, and the high chiral selectivity RD organic salt can be obtained.
(5) Synthesis of compounds of formula 6:
the compound of the formula 5 can obtain high selectivity with DE value of more than 98%, and the key intermediate (R) -2- (2, 5-difluorophenyl) pyrrolidine in the synthesis of high-quality larotretinib can be obtained by dissociating with sodium hydroxide solution, wherein the chemical purity is more than 98%, and the optical purity is more than 98%.
This step is attempted with methanol/sodium hydroxide, tetrahydrofuran/lithium hydroxide, dichloromethane/triethylamine, etc., preferably methanol/sodium hydroxide.
In a preferred embodiment, the present invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, wherein in step (1),
using ethyl titanate as a dehydrating agent and tetrahydrofuran as a solvent, and performing dehydration condensation to obtain a compound shown in a formula 2;
or the compound of the formula 2 is obtained by dehydrating and condensing isopropyl titanate serving as a dehydrating agent and tetrahydrofuran serving as a solvent;
or anhydrous copper sulfate is used as a dehydrating agent, methylene dichloride is used as a solvent, and the compound shown in the formula 2 is obtained through dehydration condensation.
In a preferred embodiment, the invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, wherein in step (2), the Grignard reagent is prepared by 2- (2-bromoethyl) -1, 3-dioxane and metal magnesium powder in tetrahydrofuran solution, or prepared by 2- (2-bromoethyl) -1, 3-dioxane and metal magnesium powder in tetrahydrofuran, and the solvent for addition reaction is one or more selected from tetrahydrofuran, diethyl ether and dichloromethane.
In a preferred embodiment, the present invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, wherein in step (3), the volume ratio of trifluoroacetic acid to water is 90:10 to 99: 1.
In a preferred embodiment, the present invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, wherein in step (3), the reaction temperature is 0-30 ℃ and the reaction time is 12-24 hours.
In a preferred embodiment, the present invention provides a method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine, wherein in step (4), the temperature of the resolution reaction is 25-70 ℃.
The method for synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine has the advantages of low cost, high optical purity, simplified subsequent separation process, easily obtained raw materials, mild process conditions and suitability for large-scale production.
The invention aims to solve the problem of synthesis of a key intermediate (R) -2- (2, 5-difluorophenyl) pyrrolidine in synthesis of a novel anticancer drug Larotrectinib, and provides a high-selectivity asymmetric synthesis method, which comprises the steps of dehydrating and condensing aldehyde and a chiral induction reagent tert-butyl sulfenamide to generate Schiff base, carrying out addition reaction with a lattice reagent to obtain a high-selectivity target compound (the optical purity EE of a crude product is more than 90%), carrying out one-step reaction through temperature and condition ring closing and reduction, and carrying out one-step separation through D-malic acid to obtain the malate with high chemical purity and high optical purity. Compared with the existing reported process, the method is simpler, has shorter steps, avoids the use of noble metal catalysts and metal organic compounds, has better safety, and obtains the (R) -2- (2, 5-difluorophenyl) pyrrolidine with better chiral purity and easy resolution.
Drawings
FIG. 1 is a graph showing the results of High Performance Liquid Chromatography (HPLC) detection of (R) -2- (2, 5-difluorophenyl) pyrrolidine prepared in example 5.
FIG. 2 is a graph showing the results of Mass Spectrometry (MS) detection of (R) -2- (2, 5-difluorophenyl) pyrrolidine prepared in example 5.
FIG. 3 is a chart showing the results of nuclear magnetic hydrogen spectrum (H-NMR) measurement of (R) -2- (2, 5-difluorophenyl) pyrrolidine prepared in example 5, the upper chart shows the full view of the nuclear magnetic hydrogen spectrum measured with 400MHz deuterated chloroform as a solvent, and the lower chart shows an enlarged view of a part of the upper chart.
Fig. 4 is a graph showing the chiral purity EE detection result of (R) -2- (2, 5-difluorophenyl) pyrrolidine prepared in example 5, in which the upper graph is a racemate HPLC spectrum, the middle graph is a pure HPLC spectrum, and the lower graph is an enlarged view of the upper graph and the middle graph.
Detailed Description
The following examples further illustrate embodiments of the present invention.
Example 1: synthesis of Compound of formula 2
The reaction solution is washed and dried in a three-neck flask, 60 g of 2, 5-difluorobenzaldehyde, 76.6 g of R-tert-butylsulfinamide, 1.0 g of PPTS and 169 g of anhydrous copper sulfate are dissolved in 500 ml of dichloromethane, heated to 40 ℃ in an oil bath, stirred, refluxed for 3-5 hours, and monitored by TLC/HPLC for reaction completion. The product was filtered and concentrated under reduced pressure. Washing and layering after dissolving; washing with saturated salt water, and layering; the schiff base of the compound of formula 2 was obtained in 100.5 g (pale yellow oil) by drying over anhydrous sodium sulfate and concentrating under reduced pressure, the yield was 97%, and the next reaction was carried out without further purification.
Example 2: synthesis of Compounds of formula 3
Dissolving 100.5 g of Schiff base compound of formula 2 in 500 ml of tetrahydrofuran, reducing the temperature to-30 ℃ under the protection of nitrogen, slowly dropwise adding 1.5 equivalents of 1mol/L Grignard reagent, keeping the temperature at about-30 ℃, reacting at constant temperature for 2-3 hours after the dropwise adding is finished, and detecting the reaction by TLC/HPLC. The reaction was quenched with saturated aqueous ammonium chloride, separated into layers, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 141.0 g (pale yellow oil) (DE > 90%) of the crude compound with a yield > 95%.
Example 3: synthesis of Compound of formula 4
141.0 g of the compound of formula 3, stirring, and slowly adding a mixture of 3L trifluoroacetic acid and water (TFA: H)2The volume ratio of O is 95:5), stirring for 1-2 hours, and controlling the temperature to be 25 ℃. Slowly adding 363 g of triethylsilane dropwise, controlling the temperature to be 30-40 ℃, controlling the temperature to be 30 ℃ after the dropwise adding is finished, stirring for 12-24 hours, and finishing the HPLC detection reaction. Concentration under reduced pressure gave 106 g of crude compound (tan liquid). The next reaction was carried out without further purification.
Example 4: synthesis of Compounds of formula 5
106 g of the compound of formula 4, 1.06 l of absolute ethanol, heating, adding 78.5 g of D-malic acid, heating and refluxing to be completely dissolved, stirring and cooling to room temperature, stirring for 2-3 hours, filtering to obtain (RR) -2, 5-difluorophenylpyrrolidine malate, stirring and washing with cold ethanol for 2-3 times, and drying to obtain 79.5 g (white-like crystal) malate compound with DE > 98%.
Example 5: synthesis of Compounds of formula 6
79.5 g of the malate compound of formula 5, 400 ml of methanol was added, 300 ml of a 1N aqueous solution of sodium hydroxide was slowly added dropwise thereto, and the mixture was stirred for 1 hour to measure the pH of the mixed solution to be 14. Concentrating under reduced pressure, adding 500 ml of methyl tert-butyl ether in turn, extracting for three times, combining organic phases, washing with saturated salt water for 1 time, drying with anhydrous sodium sulfate, and concentrating under reduced pressure to obtain 44.5 g of (R) -2- (2, 5-difluorophenyl) pyrrolidine as a light yellow oily substance with the yield of 96.95%. H-NMR (400MHz, CDC)l3) Delta 7.241-7.286(m,1H)6.926-6.983(m,1H)6.832-6.891(m,1H)4.395-4.433(m,1H)3.145-3.188(m,1H)3.052-3.095(m,1H)2.249-2.281(m,1H)2.072(s,1H)1.845-1.915(m,2H)1.625-1.656(m, 1H); LCMS (M/z,184.1, M + 1); chemical purity HPLC ═ 99.09% (Agilent 1100, YMC ODS-AQ 3UM 120A 4.6X 50MM, 210nm, ACN/H2O/buffer); chiral purity HPLC ═ 98.73% (Shimadzu LC 20A QA)&QC-HPLC-15,0.46cm I.D.. times.15 cm L.times.5 μm,220nm,10mM diammonium phosphate (pH 8.0)/acetonitrile). The detection results of the high performance liquid chromatography, the mass spectrum, the nuclear magnetic hydrogen spectrum and the chiral purity EE are respectively shown in the figures 1-4.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is intended to include such modifications and variations. The foregoing examples or embodiments are merely illustrative of the present invention, which may be embodied in other specific forms or in other specific forms without departing from the spirit or essential characteristics thereof. The described embodiments are, therefore, to be considered in all respects as illustrative and not restrictive. The scope of the invention should be indicated by the appended claims, and any changes that are equivalent to the intent and scope of the claims should be construed to be included therein.
Claims (6)
1. A synthetic method of (R) -2- (2, 5-difluorophenyl) pyrrolidine is characterized by comprising the following steps:
(1) the compound of the formula 1 and a chiral inducing reagent (R) -tert-butyl sulfenamide are subjected to dehydration condensation reaction to obtain a compound of a formula 2;
(2) carrying out addition reaction on the compound shown in the formula 2 and a Grignard reagent to obtain a compound shown in a formula 3;
(3) the compound in the formula 3 is subjected to reduction/cyclization reaction with trifluoroacetic acid and triethylsilane to obtain a compound in a formula 4;
(4) resolving the compound of formula 4 with (D) -malic acid to obtain (R) -2- (2, 5-difluorophenyl) pyrrolidine D malate compound with EE > 98% of formula 5;
(5) the compound of the formula 5 is dissociated by sodium hydroxide solution to obtain (R) -2- (2, 5-difluorophenyl) pyrrolidine
2. The method of synthesis according to claim 1, characterized in that: in the step (1), the step (c),
using ethyl titanate as a dehydrating agent and tetrahydrofuran as a solvent, and performing dehydration condensation to obtain a compound shown in a formula 2;
or the compound of the formula 2 is obtained by dehydrating and condensing isopropyl titanate serving as a dehydrating agent and tetrahydrofuran serving as a solvent;
or anhydrous copper sulfate is used as a dehydrating agent, methylene dichloride is used as a solvent, and the compound shown in the formula 2 is obtained through dehydration condensation.
3. The method of synthesis according to claim 1, characterized in that: in the step (2), the Grignard reagent is prepared from 2- (2-bromoethyl) -1, 3-dioxane and metal magnesium powder in a tetrahydrofuran solution, or the Grignard reagent is prepared from 2- (2-bromoethyl) -1, 3-dioxane and metal magnesium powder in tetrahydrofuran, and the solvent for the addition reaction is one or more selected from tetrahydrofuran, diethyl ether and dichloromethane.
4. The method of synthesis according to claim 1, characterized in that: in the step (3), the volume ratio of trifluoroacetic acid to water is 90:10-99: 1.
5. The method of synthesis according to claim 1, characterized in that: in the step (3), the reaction temperature is 0-30 ℃, and the reaction time is 12-24 hours.
6. The method of synthesis according to claim 1, characterized in that: in the step (4), the temperature of the resolution reaction is 25-70 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011437970.XA CN112624950A (en) | 2020-12-10 | 2020-12-10 | Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011437970.XA CN112624950A (en) | 2020-12-10 | 2020-12-10 | Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112624950A true CN112624950A (en) | 2021-04-09 |
Family
ID=75309169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011437970.XA Pending CN112624950A (en) | 2020-12-10 | 2020-12-10 | Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112624950A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113429328A (en) * | 2021-08-09 | 2021-09-24 | 艾琪康医药科技（上海）有限公司 | Chiral 3, 3-difluoro-4-aminopyrrolidine derivative and preparation method thereof |
| CN114933536A (en) * | 2022-03-21 | 2022-08-23 | 北京蓝博特科技有限公司 | Synthetic method of chiral intermediate of SOS1 pan KRAS inhibitor |
| CN115108957A (en) * | 2022-06-21 | 2022-09-27 | 深圳博瑞医药科技有限公司 | Synthesis method of chiral 2-phenylpyrrolidine |
| WO2023004918A1 (en) * | 2021-07-28 | 2023-02-02 | 深圳市真味生物科技有限公司 | Preparation method for synthesizing chiral nicotine from chiral tert-butyl sulfinamide |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110049987A (en) * | 2016-05-18 | 2019-07-23 | 阵列生物制药公司 | The method for preparing (S)-N- (5- ((R) -2- (2,5- difluorophenyl) pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide and its salt |
-
2020
- 2020-12-10 CN CN202011437970.XA patent/CN112624950A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110049987A (en) * | 2016-05-18 | 2019-07-23 | 阵列生物制药公司 | The method for preparing (S)-N- (5- ((R) -2- (2,5- difluorophenyl) pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide and its salt |
Non-Patent Citations (2)
| Title |
|---|
| 杨加举: "TRK抑制剂的设计、合成与生物活性评价，", 《中国优秀硕士论文全文数据库 医药卫生科技》 * |
| 邱献华等: "拉罗替尼合成路线图解", 《中国药物化学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023004918A1 (en) * | 2021-07-28 | 2023-02-02 | 深圳市真味生物科技有限公司 | Preparation method for synthesizing chiral nicotine from chiral tert-butyl sulfinamide |
| CN113429328A (en) * | 2021-08-09 | 2021-09-24 | 艾琪康医药科技（上海）有限公司 | Chiral 3, 3-difluoro-4-aminopyrrolidine derivative and preparation method thereof |
| CN114933536A (en) * | 2022-03-21 | 2022-08-23 | 北京蓝博特科技有限公司 | Synthetic method of chiral intermediate of SOS1 pan KRAS inhibitor |
| CN115108957A (en) * | 2022-06-21 | 2022-09-27 | 深圳博瑞医药科技有限公司 | Synthesis method of chiral 2-phenylpyrrolidine |
| CN115108957B (en) * | 2022-06-21 | 2023-12-29 | 深圳博瑞医药科技有限公司 | Synthesis method of chiral 2-phenylpyrrolidine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112624950A (en) | Synthesis method of (R) -2- (2, 5-difluorophenyl) pyrrolidine | |
| JPS595188A (en) | Production of 10-hydroxycamptothecin | |
| WO2015033974A1 (en) | Method for producing spirooxindole derivative | |
| CN110615744B (en) | Buvalracetam intermediate and preparation method thereof | |
| WO2021158781A1 (en) | Methods for practical synthesis of deuterated amino acids | |
| Mukai et al. | A highly diastereoselective construction of optically active bicyclo [3.3. 0] octenone derivatives from L-ascorbic acid via Pauson-Khand reaction | |
| CN113735908B (en) | Spiro-dihydrobenzothiole phosphate compound, and synthesis method and application thereof | |
| CN109180682B (en) | Chiral N-heterocyclic carbene precursor compound with bicyclic framework and preparation method thereof | |
| Yuan et al. | Reaction of aldimines and difluoroenoxysilane, an unexpected protocol for the synthesis of 2, 2-difluoro-3-hydroxy-1-ones | |
| EP3045459A1 (en) | Method for preparing intermediate compound of sitagliptin | |
| CN104837817B (en) | Synthetic route for preparation of 3-amino-piperidine compounds | |
| CN113292569A (en) | Preparation method of JAK inhibitor | |
| CN109608464B (en) | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof | |
| CN104327053A (en) | Deuterated crizotinib and derivative thereof, preparation method and application | |
| CN103896826B (en) | The method of asymmetric synthesis of (3R, 4R)-3-methylamino-4-methyl piperidine of nitrogen protection, relevant intermediate and method for preparing raw material | |
| JP4861340B2 (en) | A new synthesis of camptothecin subunits. | |
| CN113999164B (en) | Preparation method of halofuginone intermediate trans-N-benzyloxycarbonyl- (3-hydroxy-2-piperidinyl) -2-propanone | |
| EP1731509B1 (en) | Process for producing nitrogenous 5-membered cyclic compound | |
| CN103012422A (en) | Preparation and application of 5,11-methylenemorphanthridine compound | |
| CN105189524A (en) | Method for synthesizing optically active alpha-amino acid using chiral metal complex comprising axially chiral n-(2-acylaryl)-2-[5,7-dihydro-6h-dibenzo[c,e]azepin-6-yl]acetamide compound and amino acid | |
| Belov et al. | Synthesis of (3RS, 3aSR, 8aSR)-3-phenyloctahydrocyclohepta [b] pyrrol-4 (1H)-one via the aza-Cope–Mannich rearrangement | |
| CH718005B1 (en) | Process for preparing the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6 (trifluoromethyl)phenyl]methyl]- acid 3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process. | |
| CN111943959A (en) | Synthetic method of JAK inhibitor | |
| CN115108957B (en) | Synthesis method of chiral 2-phenylpyrrolidine | |
| CN107445879B (en) | Preparation method of Latricinib intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |